Encouraging data from PTX-200 ovarian cancer trial
Filed with ASX · · 3 pages · English
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Third complete response in PTX-200 AML Trial
- PTX in new CAR-T collaboration
- 1st patient dosed in trial for first in class drug PTX-100
- Receipt of R&D Tax Rebate
- Prescient Ausbiotech Ras Presentation
Later from Prescient Therapeutics
- PTX-200 High Overall Response in Ph2a Breast Cancer trial
- December 2019 Appendix 4C - Quarterly
- March 2020 Quarterly Update and Appendix 4C
- PTX-100 progresses to new dose, adds new site
- Pause in Trading
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics